cancer
mani
seriou
diseas
character
uncontrol
growth
new
blood
vessel
recent
rna
interfer
rnai
reinvigor
therapeut
prospect
inhibit
gene
express
promis
mani
advantag
bind
inhibitor
includ
high
specif
essenti
target
therapeut
articl
describ
latest
develop
use
smallinterf
rna
sirna
inhibitor
downregul
variou
angiogen
tumorassoci
factor
cellcultur
assay
anim
diseas
model
major
research
effort
current
focus
understand
gene
function
well
proofofconcept
sirnamedi
antiangiogenesi
prospect
sirna
therapeut
advantag
loom
hurdl
evalu
angiogenesi
process
gener
new
capillari
blood
vessel
preexist
blood
vessel
involv
multipl
gene
product
express
variou
cell
type
integr
sequenc
event
uncontrol
process
new
blood
vessel
growth
preexist
circul
network
import
pathogen
caus
tumor
growth
mani
blind
ocular
condit
inflammatori
diseas
angiogenesi
character
distinctli
hemangiogenesi
ha
blood
neovascular
lymphangiogenesi
la
lymphat
neovascular
latter
import
initi
step
tumor
metastasi
transplant
sensit
recent
year
much
learn
stimul
inhibitor
ha
la
member
vascular
endotheli
growth
factor
vegf
famili
emerg
prime
mediat
process
therefor
identifi
evalu
specif
inhibitor
proangiogenesi
factor
focu
antiangiogenesi
research
goal
therapeut
develop
emerg
rna
interfer
rnai
box
natur
mechan
posttranscript
gene
silenc
ptg
offer
promis
approach
develop
power
class
inhibitor
applic
angiogenesi
either
chemic
synthes
smallinterf
rna
sirna
oligonucleotid
gene
express
vector
produc
shorthairpin
rna
shrna
therapeut
agent
figur
latest
develop
use
rnai
agent
regul
angiogenesi
review
includ
studi
identifi
gene
involv
control
angiogenesi
process
effort
develop
novel
antiangiogen
therapeut
treatment
cancer
ocular
neovascular
rheumatoid
arthriti
hypoxia
inadequ
oxygen
one
key
earli
initi
angiogenesi
follow
product
nitricoxid
synthetas
respons
govern
vascular
tone
regul
growth
factor
vegf
angiopoietin
fibroblast
growth
factor
fgf
receptor
gene
involv
matrix
metabol
includ
matrix
metalloproteinas
mmp
plasminogenactiv
receptor
inhibitor
collagen
prolyl
hydroxylas
also
report
crucial
angiogenesi
function
valid
angiogen
factor
specif
role
greatli
facilit
use
rnai
inhibitor
reveal
network
involv
earli
activ
vegf
pathway
interact
among
mmp
adhes
molecul
lead
regul
signal
transduct
pathway
vegf
pathway
sever
patholog
associ
upregul
vegf
pathway
vegf
famili
consist
five
growth
factor
bind
activ
three
distinct
receptor
vegfa
bind
wherea
placent
growth
factor
pigf
vegfb
bind
vegfc
vegfd
bind
activ
intermedi
endogen
rnainterfer
process
smallinterf
rna
oligo
sirna
enabl
easytomak
easytous
gene
inhibitor
use
intracellularli
rnainduc
silenc
complex
risc
degrad
homolog
mrna
high
specif
potenc
figur
use
sirna
inhibit
gene
vitro
vivo
improv
studi
mechan
action
mani
diseas
gene
includ
involv
angiogenesi
process
capabl
use
sirna
vivo
valid
angiogenesi
factor
drug
target
uniqu
import
patholog
impact
character
accur
anim
diseas
model
emerg
clinic
viabl
deliveri
vehicl
antiangiogenesi
rnai
agent
appear
promis
unpreced
role
treatment
mani
seriou
human
diseas
result
excess
angiogenesi
vegf
receiv
consider
attent
transcript
factor
hypoxia
induc
factor
hif
key
determin
hypoxiaregul
gene
express
includ
vegf
inhibit
sirna
markedli
attenu
induct
vegf
sever
key
gene
includ
heme
oxygenas
phosphoglycer
kinas
pgk
indic
role
vegf
oxygendepend
cellcycl
regul
progesteron
receptor
pr
b
also
preferenti
regul
vegf
express
breast
cancer
cell
identifi
use
sirna
cellculturebas
assay
express
vegf
specif
inhibit
use
sirna
hela
cell
ovarian
carcinoma
cell
melanoma
cell
vegf
predomin
protein
among
major
splice
variant
vegfa
includ
vegf
vegf
vegf
vegf
amino
acid
one
compris
specif
exon
addit
differ
studi
sirna
select
block
splice
variant
vegf
vegf
show
inhibitori
function
antibodi
vegf
distinguish
variant
isoform
give
exampl
sirna
select
exist
splice
switch
vegf
inhibitor
potenti
repres
interest
point
therapeut
intervent
use
vegf
specif
sirna
reduc
level
vegf
protein
inhibit
breast
tumor
growth
intratumor
deliveri
sirna
target
vegf
demonstr
xenograft
model
parallel
studi
vegfsirna
intratumor
administr
suppress
tumor
angiogenesi
growth
also
observ
xenograft
model
eye
diseas
vegfsirna
use
inhibitor
choroid
neovascular
cnv
induc
laser
photocoagul
murin
retina
model
use
liganddirect
nanoparticl
amen
system
administr
vegfsirna
mediat
antiangiogenesi
activ
suppress
ocular
neovascular
induc
herp
simplex
viru
hsv
infect
mice
studi
use
sirna
inhibit
factor
upstream
vegf
src
homolog
domain
adaptor
protein
shb
inhibit
sirna
vegfdepend
cellular
migrat
reduc
result
loss
stimul
phosphatidylinositol
phosphoryl
focal
adhes
kinas
gener
focal
adhes
stress
fiber
format
anoth
protein
iqmotifcontain
gtpaseactiv
protein
express
endotheli
cell
ec
found
sirnamedi
knockdown
involv
vegfstimul
reactiv
oxygen
speci
product
akt
phosphoryl
endotheli
migrat
prolifer
studi
vegf
receptor
also
benefit
sirna
technolog
use
neuroblastoma
syngen
tumor
model
hsvinduc
ocular
neovascular
sirna
specif
murin
inhibit
angiogenesi
tissu
reduc
tumor
growth
ocular
neovasculatur
respect
similarli
sirna
specif
murin
also
demonstr
antiangiogen
effect
mous
ocular
model
although
vascular
basement
membran
bm
compon
sustain
growth
surviv
vascular
endothelium
mmp
vascular
integrin
emerg
key
regul
angiogenesi
import
mobil
sequest
vegf
initi
tumor
angiogenesi
wherea
specif
integrin
mediat
interact
endotheli
cell
bm
activ
integrin
receptor
signal
control
mani
key
function
prolifer
knockdown
sirna
concurr
result
increas
level
surfac
ecadherin
redistribut
bcatenin
plasma
membran
addit
physic
associ
ecadherin
cellcultur
assay
reduct
bovin
aortic
smooth
muscl
cell
basmc
migrat
caus
incub
condit
media
complet
revers
sirna
knockdown
express
indirectli
block
induct
mmp
activ
novel
mmp
regul
reck
reversioninduc
cysteinerich
protein
kazal
motif
downregul
use
sirna
caus
diminish
activ
separ
studi
sirna
knockdown
ubiquit
mint
isoform
protein
inhibit
membran
type
mmp
activ
indic
mint
protein
might
adaptor
protein
regul
traffick
mtmmp
cleavag
cellsurfac
glycoprotein
involv
cell
adhes
migrat
contribut
migrat
invas
tumor
cell
regul
mmp
suppress
metalloproteinas
inhibitor
tissu
inhibitor
enhanc
metalloproteinas
disintegrin
demonstr
sirnamedi
knockdown
differ
cellsurfac
molecul
n
identifi
potent
regul
angiogenesi
transcript
endotheli
cell
induc
vegf
rasmapk
mitogenactiv
protein
kinas
pathway
role
induct
reveal
mrna
protein
downregul
use
sirna
anoth
metalloproteas
disintegrin
character
sirna
knockdown
myoblast
cell
suggest
adhes
andor
signal
might
role
determin
pool
reserv
cell
myoblast
differenti
protein
also
recogn
key
enzym
implic
ectodomain
shed
membraneanchor
heparinbind
prohbegfdepend
epiderm
growth
factor
receptor
egfr
transactiv
sirna
pacsin
protein
bound
use
cell
inhibit
gene
attenu
shed
prohbegf
induc
tpa
angiotensin
ii
fak
crucial
role
adhes
collagen
use
fak
sirna
inhibit
express
result
strong
inhibit
adhes
collagen
also
collagen
iv
fibronectin
integrin
initi
signal
transduct
intracellular
molecul
collabor
membran
receptormedi
signal
pathway
includ
transform
growth
factor
tgf
pathway
effect
cell
adhes
statu
regul
evalu
gastric
carcinoma
cell
variant
role
smad
protein
enhanc
activ
reveal
sirna
protein
part
signal
transduct
pathway
lead
transcript
regul
multipl
cellular
process
cell
prolifer
apoptosi
differenti
effect
carcinoembryon
antigenrel
celladhes
molecul
crosslink
pancreat
adenocarcinoma
cellular
interact
extracellular
matrix
ecm
compon
vitronectin
integrin
fibronectin
integrin
character
use
sirna
knockdown
lead
increas
ecm
compon
adhes
integrinlink
kinas
ilk
stimul
express
vegf
stimul
express
pkbaktand
mtorfrapdepend
manner
sirna
inhibit
ilk
mani
signific
effect
observ
includ
inhibit
vegf
express
addit
reduc
vegfmedi
endotheli
cell
migrat
capillari
format
vitro
culmin
reduc
angiogenesi
vivo
data
demonstr
essenti
role
ilk
two
key
aspect
tumor
angiogenesi
vegf
express
tumor
cell
vegfstimul
blood
vessel
format
interestingli
wide
express
focal
adhes
protein
found
form
ternari
complex
ilk
aparvin
use
sirna
ilk
aparvin
found
crucial
promot
cell
spread
motil
cooper
role
plateletderiv
growth
factor
receptor
pdgfr
integrin
glioblastoma
cell
migrat
shown
pdgf
stimul
vitronectinadher
cell
promot
recruit
integrin
lckyesrel
novel
protein
lyn
preferenti
associ
integrin
victronectinadher
cell
presenc
absenc
pdgf
stimul
downregul
lyn
express
use
sirna
inhibit
cell
migrat
mediat
integrin
pdgfstimul
cell
fibrot
liver
fate
stellat
cell
influenc
ecm
intermediari
integrin
shown
use
sirna
silenc
v
subunit
differ
studi
microfila
found
associ
focal
contact
endotheli
cell
vimentin
express
inhibit
sirna
cell
assembl
focal
contact
smaller
normal
show
decreas
adhes
laminin
adhes
receptor
integrin
demonstr
use
sirna
target
either
subunit
key
role
invas
phenotyp
breast
carcinoma
cell
surfac
express
inhibit
addit
receptor
vegf
famili
includ
pdgf
inhibit
receptor
egfr
promis
antiangiogenesi
approach
express
block
inhibit
human
epiderm
carcinoma
cell
use
sirna
egf
induct
tyrosin
phosphoryl
lost
along
cell
prolifer
apoptosi
induc
similarli
use
retrovirusmedi
transfer
sirna
breast
ovarian
tumor
cell
exhibit
slower
prolifer
increas
apoptosi
increas
g
g
arrest
decreas
tumor
growth
sirna
also
increas
express
antiangiogen
factor
decreas
express
vegf
suggest
stimul
tumor
growth
part
regul
angiogenesi
psuper
plasmid
express
shrna
key
plasminogen
receptor
extracellular
cell
surfac
transfect
colorect
cancer
cell
rnaimedi
downregul
result
loss
plasminogen
bind
complet
loss
plasminogendepend
cellular
invas
induc
rnai
mediat
inhibit
endogen
receptor
pleiotrop
role
angiogenesi
host
immun
respons
home
tumor
metastasi
significantli
inhibit
breast
cancer
cell
migrat
vitro
furthermor
proapoptot
protein
bim
identifi
use
sirna
crucial
mediat
anoiki
epitheli
cell
commun
gproteincoupl
receptor
gpcr
egfr
signal
system
involv
cellsurfac
proteolysi
egflik
precursor
reveal
use
sirna
demonstr
role
amphiregulin
ar
prevent
gpcrinduc
egfr
tyrosin
phosphoryl
downstream
mitogen
signal
event
cell
prolifer
migrat
activ
surviv
mediat
aktpkb
studi
sirna
metalloproteasedisintegrin
tnfaconvert
enzym
tace
suppress
gpcrstimul
ar
releas
egfr
activ
downstream
event
factor
signal
transduct
pathway
vegf
promot
angiogenesi
activ
signal
pathway
includ
activ
seri
relay
protein
bind
vegf
appropri
receptor
transmit
signal
nucleu
endotheli
cell
nuclear
signal
ultim
prompt
group
gene
make
product
need
new
endotheli
cell
growth
vegf
stimul
sphingosin
kinas
spk
affect
endotheli
cell
signal
also
tumor
cell
express
vegf
receptor
bladder
tumor
cell
vegf
inhibit
reduc
cellular
sphingosin
level
rais
sirna
target
block
vegfinduc
accumul
rasgtp
phosphoerk
egfinduc
accumul
involv
reveal
sirna
diacylglycerol
kinas
dgka
hepatocyt
growth
factor
hgf
stimul
cell
migrat
impair
angiogenesi
vitro
indic
essenti
role
prolif
migratori
respons
vegf
suggest
novel
therapeut
target
control
angiogenesi
differ
studi
inhibit
sirna
decreas
prolifer
induc
apoptosi
support
notion
vegfinduc
multipl
myeloma
cell
prolifer
surviv
mediat
provid
preclin
framework
novel
therapeut
target
andor
vegf
improv
patient
outcom
multipl
myeloma
growtharrestspecif
protein
upregul
junction
membran
protein
vascular
endotheli
cadherin
vec
cell
inhibit
sirna
cell
allantoi
organ
cultur
result
endotheli
cell
could
protect
apoptosi
vegf
provid
evid
anoth
potenti
drug
target
one
key
factor
downstream
signal
transduct
pathway
vegf
receptor
braf
kinas
constitut
activ
mekerk
pathway
cell
prolifer
melanoma
cell
increas
braf
level
strongli
inhibit
sirnamedi
deplet
mutant
braf
protein
fak
silenc
use
sirna
primari
human
colon
cancer
cell
colonocyt
pressurestimul
adhes
prevent
pressureactiv
src
phosphoryl
also
ablat
integrinlink
kinaseassoci
serinethreonin
phosphatas
ilkap
select
associ
ilk
modul
cell
adhes
growth
factor
signal
ilkap
suppress
sirna
cell
entri
phase
increas
consist
antagon
ilk
role
diphosphoinositol
polyphosph
dip
also
character
sirnamedi
downregul
indic
dip
inactiv
rho
activ
rac
follow
egf
stimul
use
sirna
inhibit
protein
express
cell
modul
cellcel
adhes
phosphoryl
mapk
knock
protein
sirna
demonstr
maintain
steadyst
phosphoryl
mek
level
cell
growth
interestingli
downregul
reduc
mek
mapk
activ
could
prolong
mapk
signal
interact
thyroid
receptor
interact
protein
zyxinrel
protein
lysophosphatid
acid
lpa
receptor
induc
lpa
associ
activ
actin
rearrang
focal
adhes
assembl
cell
migrat
reveal
sirna
ovarian
cancer
cell
rnai
endogen
mechan
potent
specif
inhibit
gene
express
divert
act
cellular
gene
introduc
sirna
agent
success
power
research
tool
illustr
mani
advanc
describ
fuel
enthusiasm
sirna
novel
modal
antiangiogenesi
therapeut
larg
unmet
clinic
need
box
antivegf
sirna
treat
cancer
two
distinct
approach
achiev
antiangiogenesi
activ
cancer
treatment
activ
endogen
exogen
deliv
antiangiogenesi
factor
ii
deliv
inhibitor
reduc
activ
endogen
proangiogenesi
factor
sirna
particularli
use
inhibitor
potenc
sequencespecif
select
demonstr
induc
phenotyp
respons
cellcultur
studi
antiangiogenesi
tabl
howev
therapeut
potenti
realiz
vivo
antiangiogenesi
efficaci
sirna
agent
achiev
clinic
feasibl
deliveri
system
use
intratumor
deliveri
vegftarget
sirna
inhibit
tumor
growth
observ
mda
human
xenograft
breast
cancer
model
tumor
express
vegf
effect
reduc
vascular
tumor
growth
restor
use
box
sirna
antisens
ribozym
dnazym
rnai
newli
discov
cellular
pathway
silenc
sequencespecif
gene
mrna
level
introduct
cognat
doublestrand
rna
similarli
genesilenc
nucleic
acid
ribozym
dna
enzym
dnazym
antisens
oligonucleotid
odn
sirna
depend
hybrid
access
site
within
target
mrna
activ
howev
accur
predict
access
site
mean
facilit
reagent
design
problemat
studi
attempt
evalu
use
scan
array
effect
design
ribozym
dnazym
sirna
sequenc
target
egfr
mrna
three
type
complementari
site
effect
dosedepend
manner
use
lipofectinmedi
transfect
fact
effect
achiev
correl
case
concomit
dosedepend
reduct
egfr
protein
express
howev
ribozym
dnazym
exhibit
similar
low
potenc
ic
valu
nm
wherea
sirna
significantli
potent
ic
nm
separ
comparison
combin
plasmidexpress
antisens
sens
rna
sequenc
effect
express
asrna
alon
target
gene
knockdown
express
srna
alon
effect
furthermor
potenc
sirna
target
report
gene
luciferas
one
order
magnitud
stronger
phosphorothio
asdna
overal
mani
studi
compar
effici
gene
silenc
sirna
nucleic
acid
inhibitor
find
case
better
sirna
potenc
system
administr
aqueou
vegf
sirna
fail
show
sign
target
inhibit
report
local
deliveri
sirna
tumor
effect
vegf
express
differ
studi
intratumor
deliveri
vegf
sirna
cation
carrier
result
dramat
suppress
angiogenesi
growth
preclin
studi
illustr
grow
interest
sirnabas
antiangiogenesi
therapeut
treatment
cancer
recogn
local
deliveri
antitumor
agent
limit
tumor
type
clinic
relev
therefor
system
administr
sirna
provid
greatest
clinic
benefit
treatment
especi
dissemin
metastat
cancer
end
vegfpathway
sirna
agent
vivo
valid
activ
evalu
system
administr
mice
bear
neuroblastoma
tumor
use
liganddirect
nanoparticl
carrier
exhibit
inhibit
target
express
angiogenesi
tumor
growth
repeat
dose
observ
efficaci
achiev
potenc
amen
clinic
applic
strengthen
promis
sirna
therapeut
modal
antivegf
sirna
treat
ocular
neovascular
diseas
new
uncontrol
blood
vessel
develop
eye
pivot
process
pathogenesi
sever
ocular
neovascular
nv
diseas
includ
agerel
macular
degener
amd
diabet
retinopathi
ra
herp
simplex
viru
hsv
induc
stromal
kerat
sk
ocular
diseas
often
lead
blind
unfortun
manag
therapeut
challeng
system
administr
liganddirect
nanoparticl
carri
antivegf
sirna
mous
sk
model
appli
measur
antiangiogenesi
therapeut
potenti
studi
potent
sirna
target
vegfa
valid
first
vitro
mix
polym
conjug
form
nanoparticl
nm
diamet
box
trifunct
polym
compos
branch
polyethylenimin
one
end
polyethylen
glycol
peg
middl
rgd
peptid
motif
end
polym
found
self
assembl
neg
charg
sirna
particl
rgd
peptid
expos
surfac
rgd
peptid
specif
ligand
integrin
activ
endotheli
cell
neovasculatur
diseas
tissu
peg
help
prevent
nonspecif
bind
tissu
vegf
sirna
deliv
liganddirect
endocytosi
comparison
subconjuctiv
administr
sirna
result
weaker
shorter
antiangiogenesi
efficaci
addit
combin
sirna
target
three
proangiogenesi
gene
vegf
achiev
stronger
efficaci
sirna
target
one
three
proangiogenesi
gene
use
differ
model
feasibl
sirnamedi
antiangiogenesi
retin
cell
vitro
murin
retina
vivo
evalu
sirna
specif
murin
human
vegf
test
vitro
use
chemic
induc
hypoxia
modul
endogen
vegf
express
vivo
studi
evalu
effect
nake
sirna
level
vegf
perform
first
coinject
recombin
adenovirus
carri
enhanc
greenfluoresc
protein
egfp
hvegf
cdna
use
laserinduc
choroid
neovascular
cnv
along
subretin
deliveri
appropri
sirna
mice
sirna
effect
specif
inhibit
hypoxiainduc
hvegf
level
human
cell
line
adenoviralexpress
hvegf
vivo
subretin
deliveri
mvegfsirna
significantli
inhibit
cnv
laser
photocoagul
mice
antiangiogenesi
sirna
treat
rheumatoid
arthriti
rheumatoid
arthriti
ra
one
sever
articular
diseas
character
synovi
hyperplasia
follow
impair
joint
function
sever
impact
qualiti
life
although
mechan
regul
synovi
cell
outgrowth
fulli
understood
evid
vegf
import
role
develop
ra
patient
ra
serum
basic
fibroblast
growth
factor
bfgf
vegf
concentr
increas
patient
treat
steroid
synovi
fluid
level
bfgf
vegf
reduc
investig
polymorph
vegf
gene
patient
ra
relationship
clinic
featur
radiograph
progress
joint
diseas
indic
frequenc
two
haplotyp
cgct
aagt
significantli
increas
patient
ra
compar
control
vegf
receptor
inhibitor
caus
dosedepend
reduct
vascular
mous
ra
model
inhibit
knee
swell
antigeninduc
arthriti
inhibit
sever
score
global
histolog
score
mous
model
furthermor
treatment
use
infliximab
antitnfa
antibodi
result
reduct
solubl
adhes
molecul
vegf
achiev
rapid
suppress
diseas
activ
indic
patholog
ra
close
relat
overexpress
vegf
one
signatur
ra
joint
overexpress
tnf
cytokin
induc
angiogenesi
inflamm
tissu
therefor
use
sirna
inhibitor
modul
relev
pathway
might
provid
therapeut
potenti
treatment
ra
primari
ra
synovi
fibroblast
rasf
treat
tnfa
sever
gene
select
use
microarray
analysi
base
upon
differenti
express
statu
use
sirna
downregul
one
gene
tnfainduc
flicelik
inhibitori
protein
flip
like
gene
significantli
enhanc
apoptosi
decreas
prolifer
decreas
product
tnfastimul
rasf
akt
protein
kinas
b
import
role
tnfarel
apoptosisinduc
ligand
trail
mediat
apoptosi
rheumatoid
synovi
cell
use
sirna
inactiv
akt
significantli
increas
trailmedi
apoptosi
synovi
cell
mutat
human
gene
code
cryopyrin
identifi
continuum
inflammatori
disord
cryopyrin
mutant
induc
potent
nfkb
activ
depend
express
asc
apoptosisassoci
specklik
protein
contain
caspas
recruit
domain
adaptor
protein
previous
suggest
mediat
cryopyrin
signal
induct
cryopyrin
activ
result
asc
bind
secret
effect
abolish
inhibit
asc
express
sirna
even
though
efficaci
data
report
use
sirna
revers
ra
patholog
anim
diseas
model
potenti
applic
promis
downregul
racaus
cytokin
receptor
vegf
signal
factor
box
cocktail
sirna
target
multipl
gene
mani
human
diseas
result
overexpress
multipl
endogen
exogen
pathogen
gene
angiogenesisrel
diseas
repres
typic
characterist
caus
abnorm
overexpress
multipl
gene
moreov
diseas
progress
develop
drug
resist
also
circumv
effect
singledrug
treatment
one
strategi
overcom
hurdl
use
combin
multipl
drug
sirna
provid
uniqu
advantag
combin
therapi
combin
multipl
sirna
oligo
target
multipl
diseasecaus
gene
without
dramat
differ
drug
chemic
properti
combin
sirna
target
vegfa
demonstr
improv
antiangiogenesi
potenc
compar
sirna
target
one
factor
combin
appear
achiev
synergist
effect
knockdown
three
target
simultan
result
potent
antiangiogenesi
efficaci
antiangiogen
molecul
fall
five
main
categori
accord
mode
action
inhibitor
proangiogen
growth
factor
correspond
receptor
vegf
bfgf
fgf
receptor
pdgf
ii
proteas
inhibitor
prevent
breakdown
surround
matrix
need
bloodvessel
growth
iii
endogen
inhibitor
angiogenesi
endostatin
iv
inhibitor
cellular
adhes
molecul
v
molecul
undefin
mechan
owe
complic
angiogenesi
pathway
combin
multipl
sirna
target
angiogen
factor
categori
might
enabl
identif
potent
antiangiogen
agent
potenti
therapeut
applic
strategi
appli
attempt
achiev
stronger
antisar
coronaviru
activ
remark
success
either
individu
sirna
combin
repres
novel
approach
treatment
ra
conclud
remark
sirna
power
antiangiogenesi
agent
modul
angiogenesi
pathway
use
sirna
inhibitor
gene
express
proven
power
approach
valid
gene
function
relev
factor
vitro
vivo
rapid
develop
experiment
evid
improv
understand
angiogenesi
approach
intervent
clearli
demonstr
power
rnai
uniqu
advantag
previou
method
genefunct
studi
includ
nucleic
acid
inhibitor
antisens
ribozym
dnazym
inform
obtain
individu
factor
contribut
global
understand
angiogenesi
also
provid
strong
support
effort
develop
novel
therapeut
treatment
variou
angiogenesi
diseas
includ
cancer
ocular
neovascular
diseas
rheumatoid
arthriti
nonetheless
although
vivo
studi
describ
articl
provid
groundwork
potenti
therapeut
applic
rnai
technolog
thorough
preclin
studi
pharmacolog
toxicolog
specif
sirna
therapeut
candid
remain
report
reveal
occurr
incomplet
select
sirna
oligo
includ
offtarget
effect
activ
interferon
rais
concern
safeti
unwant
side
effect
fair
say
studi
base
upon
cellcultur
experi
without
support
vivo
studi
recent
studi
use
system
deliveri
intraperiton
intraven
nake
sirna
duplex
mice
indic
lack
interferon
respons
compar
polyinosin
acid
polycytidyl
acid
poli
c
analog
longdsrna
ligand
tolllik
receptor
clinic
viabl
deliveri
emerg
sirna
inhibitor
achiev
therapeut
efficaci
sever
anim
diseas
model
angiogenesi
dualtarget
therapeut
box
combin
sirna
target
multipl
proangiogenesi
factor
demonstr
advantag
box
dualtarget
antiangiogenesi
therapeut
inhibit
express
drugtarget
gene
sirna
quit
differ
inhibitori
action
convent
drug
monoclon
antibodi
smallmolecul
inhibitor
bind
inhibit
exist
protein
repres
novel
distinct
class
therapeut
inhibitor
probabl
differ
rang
applic
drug
target
albeit
substanti
overlap
importantli
select
convey
gene
sequenc
could
potenti
stringent
singl
nucleotid
differ
two
gene
promis
aid
therapeut
approach
provid
much
better
target
select
addit
use
tissuetarget
nanoparticl
deliveri
liganddirect
tissu
select
enabl
potenti
dualtarget
therapeut
approach
one
uniqu
use
enhanc
extracellular
stabil
sirna
agent
avoid
effect
target
gene
normal
tissu
increas
activ
sirna
diseas
tissu
figur
use
system
deliveri
sirna
target
vegf
pathway
factor
site
neovascular
antiangiogenesi
efficaci
achiev
neuroblastoma
tumor
model
hsvinduc
mous
ocular
sk
model
identifi
ligand
bind
adhes
molecul
integrin
receptor
tissuetarget
deliveri
sirna
agent
provid
synergist
effect
improv
antiangiogenesi
efficaci
layer
selfassembl
sirna
nanoparticl
system
use
deliv
sirna
specif
gene
involv
vegf
pathway
achiev
dualtarget
antiangiogenesi
therapeut
effect
first
target
effect
achiev
use
rgd
peptid
surfac
ligand
nanoparticl
target
integrin
express
tumor
neovasculatur
thu
avoid
effect
target
gene
normal
tissu
second
target
effect
achiev
use
sirna
specif
gene
involv
vegf
pathway
vegf
inhibit
angiogenesi
activ
target
tumor
tissu
thu
gener
antitumor
efficaci
novel
therapeut
modal
emerg
technolog
mani
issu
relat
sirna
therapeut
must
address
dilig
success
novel
approach
achiev
clinic
